Year All2024202320222021202020192018201720162015 Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma September 16, 2024 Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting September 5, 2024 Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma September 4, 2024 Poseida Therapeutics to Present at Upcoming Investor Conferences August 29, 2024 Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024 August 5, 2024 Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum July 1, 2024 Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders June 3, 2024 Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024 May 14, 2024 Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting May 9, 2024 Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology May 1, 2024
Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma September 16, 2024
Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting September 5, 2024
Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma September 4, 2024
Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024 August 5, 2024
Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum July 1, 2024
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024 May 14, 2024
Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting May 9, 2024
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology May 1, 2024
